Yamazoe Masatoshi, Tomioka Hiromi
Department of Respiratory Medicine, Kobe City Medical Center West Hospital, Kobe, Japan.
BMJ Open Respir Res. 2018 Oct 9;5(1):e000342. doi: 10.1136/bmjresp-2018-000342. eCollection 2018.
In 2016, an international working group proposed a revised definition and new diagnostic criteria for the acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF). Based on these criteria, AE-IPF was diagnosed regardless of the presence or absence of a known trigger and categorised as triggered (T-AE) or idiopathic (I-AE) AE-IPF. However, the clinical characteristics of the newly defined AE-IPF and clinical differences between T-AE and I-AE are unresolved.
We retrospectively analysed 64 patients with AE-IPF (I-AE (42), T-AE (22)) admitted to our hospital over a 10- year period.
I-AE and T-AE cases did not show differences in in-hospital and long-term outcomes (in-hospital mortality: I-AE 52.4%, T-AE 59.1%, p=0.61; long-term mortality: p=0.68). In the I-AE group, significantly more patients received corticosteroid therapy before an AE (I-AE 35.7%, T-AE 4.5%; p=0.01). Significantly more patients in the T-AE group had lung cancer (I-AE 7.1%, T-AE 59.1%, p<0.001). I-AE occurred more frequently in winter while T-AE did not show seasonality. The white blood cell (WBC) count and haemoglobin (Hb) level were independent predictors of in-hospital deaths in I-AE (WBC: OR 1.87; 95% CI 1.09 to 4.95, p=0.01; Hb: OR 0.26, 95% CI 0.04 to 0.78, p=0.01) but not T-AE.
With the introduction of new criteria for AE-IPF, a retrospective study over a 10-year period showed a lack of prognostic difference between I-AE and T-AE. The WBC count and Hb level predicted in-hospital outcome in I-AE cases.
2016年,一个国际工作组提出了特发性肺纤维化急性加重(AE-IPF)的修订定义和新诊断标准。基于这些标准,无论是否存在已知诱因,均可诊断AE-IPF,并将其分为有诱因的(T-AE)或特发性(I-AE)AE-IPF。然而,新定义的AE-IPF的临床特征以及T-AE和I-AE之间的临床差异仍未明确。
我们回顾性分析了我院10年间收治的64例AE-IPF患者(I-AE(42例),T-AE(22例))。
I-AE和T-AE病例在住院及长期预后方面无差异(住院死亡率:I-AE为52.4%,T-AE为59.1%,p = 0.61;长期死亡率:p = 0.68)。在I-AE组中,显著更多患者在AE发作前接受了糖皮质激素治疗(I-AE为35.7%,T-AE为4.5%;p = 0.01)。T-AE组中患有肺癌的患者显著更多(I-AE为7.1%,T-AE为59.1%,p < 0.001)。I-AE在冬季更频繁发生,而T-AE无季节性差异。白细胞(WBC)计数和血红蛋白(Hb)水平是I-AE患者住院死亡的独立预测因素(WBC:OR 1.87;95%CI 1.09至4.95,p = 0.01;Hb:OR 0.26,95%CI 0.04至0.78,p = 0.01),但在T-AE中并非如此。
随着AE-IPF新诊断标准的引入,一项为期10年的回顾性研究表明I-AE和T-AE在预后方面无差异。WBC计数和Hb水平可预测I-AE患者的住院结局。